The mRNA and protein levels of Atg7 were both decreased in ARC pretreatment group, thus indicating that ARC might protect liver from ConA-induced hepatitis through the inhibition of the upregulation of Atg7. The gene discussed is ATG7; the disease is hepatitis A virus infection.